47 Protein Therapies Companies - Worldwide
Search through all Protein Therapies companies with powerful filtering options
Company Name | Location | About |
|---|---|---|
Seattle, Washington, United States | A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Our experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. Our computational platform, AlphaBind, is trained on the world’s largest protein-protein interaction database and predicts binding strength from sequence. A-Alpha Bio leverages AlphaSeq and AlphaBind for in-house therapeutic programs and in partnership with leading pharmaceutical companies to inform the discovery and development of novel therapeutics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/ | |
Cambridge, Massachusetts, United States | Acquired by Merck (Nasdaq: MRK) on 11/22/2021 Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts. | |
Boston, Massachusetts, United States | Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications. The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that have the potential for oral delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND enabling studies. | |
Taipei, Songshan 105, TW | Allgenesis is a privately-held, clinical stage ophthalmology company based in Taiwan. The company is focused on novel multi-specific fusion proteins for treating diabetic macular edema and wet-age-related macular degeneration; and small molecule eye drops for dry eye and pterygium diseases. | |
Seattle, WA | Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines. | |
Boston, Massachusetts, US | Asimov's mission is to advance humanity's ability to design living systems, enabling biotechnologies with outsized societal benefit. The company is developing a synthetic biology platform from cells to software to design and manufacture next-generation therapeutics, including cell & gene therapies, through a combination of products, services, & collaborations. Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million. | |
San Fransisco, US | Avenue Biosciences is a biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers. Headquartered in San Francisco, USA, and with laboratory operations in Helsinki, Finland, Avenue Biosciences has developed a protein engineering platform that combines organic biologics and machine learning to boost protein production. The proprietary method is based on years of scientific research from the University of Helsinki, Finland. Our goal is to drive significant progress in biotechnology by providing turnkey solutions that streamline production, improve quality, and unlock new therapeutic possibilities. We're a team of brilliant minds, each an expert in their field, united by a shared mission to make a real impact in a novel area of biotechnology. We are a highly experienced, entrepreneurial minded team with an impressive scientific background, that lives and breathes a casual, committed, and positive culture and spirit. | |
Durham, North Carolina, United States of America | BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. We are a commercial-stage biotech company with US headquarters in Durham, North Carolina. Our European headquarters is in Dublin, Ireland, and our Discovery Center of Excellence is rooted in Birmingham, Alabama, with many other regional offices around the world. As world leaders in structure-guided drug design, we draw on the strengths and expertise of all our colleagues—from those of us in the field or behind the scenes in our labs, to others based in home offices and around the globe. To view our LinkedIn community guidelines, please visit bit.ly/BCRXGuidelines. | |
Žirmūnų gatvė 139a, Vilnius, 09120, LT | Biomatter (previously called Biomatter Designs) is a synthetic biology company that creates new proteins for health and sustainable manufacturing applications. The company has developed the Intelligent Architecture™ platform that addresses limitations of current engineering approaches to unlock completely new horizons for protein design and development. | |
Berkeley, California, United States | Biomonadic is an early stage techbio startup leveraging AI and IoT to resolve critical supply chain bottlenecks affecting the cell and gene therapy (CGT). They are creating a next generation AI empowered data platform for biotech manufacturing, leveraging reinforcement learning and LLMs to augment their capabilities. | |
Uiwang-si, South Korea | BMI Korea is a dynamically-growing pharmaceutical company that implements technical cooperation and joint development with a broad spectrum of global pharmaceutical companies and institutions. They are known for their work in advancing subcutaneous drug delivery and developing recombinant hyaluronidase. BMI Korea is a well-known manufacturer of pharmaceutical products and is always challenging for the healthy life of human beings. | |
Boulder, Colorado, United States | Bolder BioTechnology has a diversified pipeline of proprietary, long-acting human protein pharmaceuticals that include potential treatments for hematological and endocrine disorders, cancer supportive care, and orphan genetic diseases. | |
Seattle, Washington, United States | Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines. | |
Boston, Massachusetts, United States | BrickBio's engineered RNA and protein-chemistry platform technology enables custom tailoring of any protein with homogenous, site-specific and site-selective bioconjugation modifications, enabling novel classes of biologics with superior therapeutic windows and characteristics such as half-life, dosage, and efficacy. Having validated its precise and unrestricted conjugation capabilities through pharmaceutical co-development partnerships, the company is building its internal oncology and immunology pipeline by creating unique antibody and bispecific-conjugates while additionally pioneering spatial protein assembly for Precise Protein Origami™. | |
St. Louis, Missouri, United States | Canopy Biosciences, a Bruker company, empowers innovation by providing access to cutting-edge spatial biology and multi-omic tools so biomedical researchers can drive scientific discovery faster. Our proprietary technology ChipCytometry™ is a quantitative multiplex immunofluorescence imaging method for the spatial analysis of complex tissues and mapping of cell populations with single-cell resolution. Supported by Canopy Spatial Services™ with our CLIA-certified laboratory, we provide a unique collection of spatial and single-cell technologies that accelerate the understanding of cellular diversity and interaction. Learn more at CanopyBiosciences.com. | |
South San Francisco, California, United States | Culture is your bioreactor lab, in the cloud. We help scientists accelerate bioprocess development with our high-throughput bioreactor cloud lab. You design your experiment, and we execute the experiment in our lab using our 250mL bioreactors. We take care of the high-quality execution so that you can focus on developing processes. While your experiment runs in our lab, you can monitor and analyze your data in real time using our online dashboard. With Culture, get faster insights to make better, data-driven decisions. | |
Suzhou, China | Eluminex Biosciences is a clinical-stage biotechnology company focused on development and commercialization of innovative therapeutics to fulfill unmet medical needs in the treatment and management of ophthalmic diseases. | |
La Jolla, California, United States | Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-LockTM platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics. | |
330 north wabash avenue, chicago, illinois, united states | Evozyne designs novel protein therapeutics to solve previously unaddressable patient needs. | |
Haverhill, Suffolk, United Kingdom | Getting genetic syntax right. With precise use of genetic grammar in transgenic design, ExpressionEdits unlocks the capacity to make proteins previously beyond reach. | |
Boston, Massachusetts, United States | Fable Therapeutics Inc. was founded with a conviction to revolutionize drug discovery through the purposeful integration of AI techniques. Our cross-functional team of ML scientists and drug hunters collaborate to design novel medicines with expanded therapeutic potential. With this passion and vision, we’re designing the future of drug discovery. | |
Cambridge, Massachusetts, United States | Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple transformative human health and sustainability products. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures. The current Flagship ecosystem comprises over 40 companies, including Denali Therapeutics, Foghorn Therapeutics, Generate:Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics. | |
Somerville, Massachusetts, United States | Generate:Biomedicines is a new kind of therapeutics company—existing at the intersection of machine learning, biological engineering, and medicine—pioneering generative biology to create breakthrough medicines. Through The Generate Platform, we are able to expand the breadth of technical possibilities in order to fundamentally change the way medicines are made. | |
700 main st, cambridge, massachusetts, united states, 02139-3543 | Gensaic is spearheading the development of multi-functional proteins for the dimensional delivery of therapeutics. Gensaic's mission is to decode the language of dimensional delivery: delivery with precision at the tissue, cell and subcellular dimensions. The team is writing the anthology of multi-functional delivery proteins with the FORGE platform, combining generative protein modeling and in-vivo protein evolution. | |
Glasgow, Scotland, United Kingdom | Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens. | |
Pagliuca Harvard Life Lab, 127 Western Ave., Boston, MA 02134, US | GRO Biosciences transforms protein therapeutics with new amino acid building blocks to treat incurable diseases. | |
Yuseong-gu, Daejeon, South Korea | At ILIAS Biologics, we dedicate ourselves to the paradigm-shifting advances in human medicine. We are specialized in developing engineered exosomes by loading large therapeutic payloads inside exosomes via our proprietary platform technology, EXPLOR®. By harnessing the power of our engineered exosomes, we can deliver therapeutic proteins to the undruggable intracellular pathways to treat life-threatening and hard-to-treat rare diseases. With a strong belief and the power of open innovation, we are expanding our global network of research and business alliances to maximize our potential in the development of the novel exosome platform technology. | |
London, United Kingdom | Intract Pharma is a biotechnology company innovating in the field of oral delivery of complex proteins such as monoclonal antibodies with a special focus on treatment of gastrointestinal and systemic immune-mediated inflammatory diseases. Intract is applying it’s Phloral™ and Soteria™ technology platform for precision delivery of proteins to the colon for local tissue and systemic immunomodulation. Our vision is to transform care for millions of patients suffering from chronic diseases by converting their potent injectable biologic medicines into safe, effective and convenient take-at-home pills. | |
Cambridge, Massachusetts, United States | Marketing endless RNA (eRNA™) — a class of programmable medicines capable of expressing therapeutic proteins insidethebody, eRNA is based on long non-coding (lnk) RNA. | |
Cambridge, United Kingdom | Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins. | |
Zurich, Switzerland | Nerai Bio is a biotech startup pioneering ultra-specific genome editing technologies to treat genetic diseases. Using their AI-driven MORPHEME platform, they engineer novel gene-editing proteins that can precisely target and correct DNA at any location, addressing a broader range of genetic mutations than existing tools like CRISPR. Their lead therapeutic candidates focus on severe liver disorders, aiming to provide a single, permanent cure for conditions currently treated with lifelong care. Recently, Nerai Bio secured CHF 150,000 from Venture Kick to advance business development, preclinical validation studies, and partnerships. | |
Boston, MA | At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine. In response to recent recruitment fraud, visit our Careers page to verify all job opportunities and read our guidance on this topic: https://odysseytx.com/careers/ | |
Cambridge, Massachusetts, United States | Orbital Therapeutics is building a first-in-kind platform at the intersection of RNA technology, delivery methods, data science and automation to develop an expansive portfolio of RNA-based medicines to treat disease in humans. | |
2641 Osprey Vista Way UT Research Park | At Orio Therapeutics, our mission is to save lives by making the regenerative medicine dream accessible and a wide-spread reality. We are dedicated to developing novel regenerative drugs with increased efficacy and reduced side-effects, using cutting-edge targeted drug-delivery technologies to create novel therapeutic proteins. Notably, we strive to demonstrate that efficient drug delivery technologies are not confined to the development of complex devices and drug carriers but can be achieved based on clever molecular designs. We aim to initially validate our program pipeline through the development of a therapeutic molecule for myocardial infarction that has the potential to change the lives of patients following myocardial infarction by enabling faster recovery time and improved heart function. | |
Cambridge, MA | Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics or SMThs, designed to address complex diseases by targeting rare combinations of proteins that work together. Using its proprietary Locksmith platform, the company is advancing programs across multiple therapeutic areas to create new options for patients with common, hard-to-treat conditions. | |
Barcelona, Catalonia | Peptomyc is a company focused on the development of a new generation of cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. | |
Headquarters address not available | RenBio was founded on the principle that the remarkable medical benefits of antibody therapeutics should be available to everyone, and was named one of DARPA’s “Biotech Startups of the Future” one year after opening its operations. The company was co-founded by David D. Ho, MD (Time magazine's "Man of the Year" in 1996 and recipient of the Presidential Citizens Medal) and Yaoxing Huang, PhD, visionary scientists affiliated with the Aaron Diamond AIDS Research Center and Professors at Columbia University Medical Center. RenBio is backed by the Bill & Melinda Gates Foundation, DARPA, and a syndicate of private investors, and is headquartered at the Alexandria Center® for Life Science in New York City. | |
1-9-10 Horidome-cho, Nihonbashi, Chuo-ku, Tokyo, JP | RevolKa is a pioneer of next-generation protein engineering. We are committed to the discovery and development of innovative proteins by leveraging our proprietary artificial intelligence-integrated directed protein evolution technology, called aiProtein®. RevolKa is open to research collaboration opportunities with partners and also co-development of our internal assets. About aiProtein® RevolKa innovatively integrated directed protein evolution with the transformative digital technology, artificial intelligence (AI) to create a proprietary powerful protein engineering technology, called aiProtein®. aiProtein® remarkably accelerates directed protein evolution and enables to create unprecedented engineered proteins. This platform is a robust solution for biologics engineering, for example, to address issues in developability and manufacturability of therapeutic antibodies. aiProtein® enables multi-dimensional simultaneous engineering for protein properties, such as efficacy, affinity, physicochemical properties, immunogenicity, species cross-reactivity, and so on. | |
Cambridge, Massachusetts, United States of America | SmartPharm Therapeutics, now a subsidiary of Sorrento Therapeutics, is a gene therapy company applying the next generation of non-viral DNA and RNA technologies to treat serious human diseases. Founded with the vision of producing “Biologics from Within,” SmartPharm is focused on bringing together unique technology and developmental capabilities for the treatment of rare diseases including lysosomal storage disorders. SmartPharm Therapeutics is a second-generation gene-encoded therapeutics company that has benefited from the first decades of learning in gene therapy development to produce an evolved therapeutic platform. We integrate these insights with key technologies and engineering capabilities to enable us to produce optimal gene-encoded therapeutics for patients. | |
San Diego, California, United States | Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. Stemedica has developed a proprietary manufacturing technology platform that produces allogeneic progenitor cell products with intellectual property protection under a low-oxygen, low-tension environment in a cGMP-compliant manufacturing facility. The company's lead drug candidate, ischemia-tolerant mesenchymal stem cells, or itMSCs, is an allogeneic progenitor cell therapy currently in clinical development for the treatment of ischemic stroke and Alzheimer’s disease. The company’s second drug candidate, ischemia-tolerant neural progenitor cells, or itNSCs, is an allogeneic cell therapy currently in development for spinal cord injury. In addition, Stemedica is developing progenitor multi-cell therapy (itMSCs and itNSCs) for ischemic stroke and progenitor cell and protein combination therapy for Alzheimer’s disease. More information on Stemedica may be found at www.stemedica.com. | |
Seattle, Washington, United States | Talus Bioscience is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus Bio spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology. Talus Bio's platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for about 1,000 gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics. As a company, Talus Bio focuses on two parallel efforts to prove that our technology can open up the world of gene regulation for drug discovery: - Developing internal programs against previously undruggable gene regulators in cancers with poor standard of care - Partnering with pharma, biotech, and academic labs to help progress their pipeline of gene regulator drugs | |
Plaza Cein, Noáin, Chartered Community of Navarre 31110, ES | Telum Therapeutics SL is a global drug discovery biotechnology company specializing in the use of Innovative Phage Lytic Proteins as antibiotics. | |
Frederick, Maryland, United States | Developed a computational platform that converts recombinant proteins intomaterial-binding variants that can be used to coat implants, devices, and injectable carriers. | |
TherapyX Headquarters, Buffalo, New York, United States | TherapyX Inc. is changing the future of pharmaceuticals using revolutionary technology. They encapsulate large biological molecules in an orally ingestible form, allowing these molecules to remain fully intact. | |
Columbus, Ohio, United States | We are a US biotech company focused on restoring cell health and resilience, with profound initial indications for the treatment of cancers and rare diseases, the protection of multiple organ injuries, and the effective reversal of aging. We are looking for investors, development partners, or licensees. Interested parties please contact us for further information and discussions. | |
Scarborough, Maine, US | ||
seattle, washington, united states | ZipBio is a biotech startup revolutionizing AI drug discovery with our cutting-edge protein design and drug discovery platform. We specialize in compressing biology to accelerate therapeutic innovation. |